Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- LIXTW
- Price
- 0.04
- Stock movement up
- +- (%)
- Company name
- Lixte Biotechnology Holdings Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- -
- Ent value
- -1.31M
- Price/Sales
- -
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 69.30%
- 1 year return
- -54.88%
- 3 year return
- -40.15%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-11
DIVIDENDS
LIXTW does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | - |
| EV to Sales | - |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | - |
| EPS (TTM) | -1.78 |
| FCF per share (TTM) | -1.54 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -3.99M |
| Net income (TTM) | -4.00M |
| EPS (TTM) | -1.78 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 1.64M |
| Net receivables | 0.00 |
| Total current assets | 1.69M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 1.70M |
| Accounts payable | 72.86K |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 328.96K |
| Total liabilities | 328.96K |
| Shareholder's equity | 1.37M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -3.47M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -3.47M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -292.66% |
| Return on Assets | -235.90% |
| Return on Invested Capital | -292.66% |
| Cash Return on Invested Capital | -253.70% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.04 |
| Daily high | 0.04 |
| Daily low | 0.04 |
| Daily Volume | 1K |
| All-time high | 1.30 |
| 1y analyst estimate | - |
| Beta | -0.17 |
| EPS (TTM) | -1.78 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| LIXTW | S&P500 | |
| Current price drop from All-time high | -97.02% | -10.49% |
| Highest price drop | -98.46% | -56.47% |
| Date of highest drop | 5 Mar 2025 | 9 Mar 2009 |
| Avg drop from high | -81.06% | -11.07% |
| Avg time to new high | 549 days | 12 days |
| Max time to new high | 1081 days | 1805 days |
COMPANY DETAILS
Marketcap
-
Marketcap category
Small-cap
Description
LIXTE Biotechnology Holdings, Inc., a clinical-stage pharmaceutical company, focuses on identifying targets for cancer drug development, and developing and commercializing cancer therapies. Its lead product candidate, LB-100 is in phase 1b clinical trials combined with Atezolizumab for patients with microsatellite stable metastatic colon cancer. The company's Phase 1b portion of its advanced soft tissue sarcoma clinical trial seeks to determine appropriate dosing and toxicity for treating soft tissue sarcomas with combination of LB-100 and standard-of-care chemotherapy; and LB-100 combined with dostarlimab that is in phase 1b/2 for ovarian clear cell carcinoma. The company has a clinical trial research agreement with the Netherlands Cancer Institute; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group; and a development collaboration agreement with the Netherlands Cancer Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.
Employees
3
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner